Lenomorelin

DCTPepD ID  DCTPepD0068

Active Ingredients   Lenomorelin

Description  A 28 amino acid peptide hormone that was originally isolated from the stomach as the endogenous ligand for the growth hormone secretagogue receptor (GHSR). Ghrelin and its receptor are expressed in a number of cancers and cancer cell lines and may play a role in processes associated with cancer progression, including cell proliferation, apoptosis, and cell invasion and migration.

Synonyms  Ghrelin; Ghrelin human; Human acylated ghrelin; Ghrelin (human); Lenomorelin

Disease  Cancer

Classification

  

Peptide and derivative Hormone and analogue

Structure Information


Molecular Formula  C149H249N47O42

Molecular Weight  3370.9

Active Sequence  GXSFLSPEHQRVQQRKESKKPPAKLQPR

Sequence Length  28

Modification  X=Ser(octanoyl)

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  91668172

DrugBank Accession Number  DB11895

NCI Thesaurus Code  C170105  

UNII  UXG268Q86R   GSRS

CAS  258279-04-8



Drug approval


Drug indication
    Lenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism, Hypopituitarism, and Frailty Syndrome, among others.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00681486 Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss Cancer Phase 3 Treatment
NCT00933361 Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study Advanced Cancer; Cachexia Phase 1/2 Treatment
NCT02913703 Effect of Preprandial Ghrelin on Postprandial Glucose Tolerance Type 2 Diabetes Phase 1 Basic Science

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.